Blastic plasmacytoid dendritic cell neoplasm: Extensive disease, Langer lines, and blood burden in a retrospective study of 66 cases - 17/12/24
Doi : 10.1016/j.jaad.2024.11.010
Christopher J. Fay, MD a, Jesse P. Hirner, MD b, Shai Shimony, MD c, d, e, Ai-Tram Bui, MD f, Andrew A. Lane, MD, PhD c, d, Nicole R. LeBoeuf, MD, MPH a, d, ⁎ 
a Department of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts
b Department of Dermatology, University of Missouri Health Care, Columbia, Missouri
c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
d Harvard Medical School, Boston, Massachusetts
e Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Israel
f Department of Dermatology, Stanford University Medical Center, Stanford, California
∗Correspondence to: Nicole R. LeBoeuf, MD, MPH, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, 450 Brookline Avenue, Boston, MA 02115Center for Cutaneous OncologyDana-Farber/Brigham Cancer Center450 Brookline AvenueBostonMA02115
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Tuesday 17 December 2024
Key words : blastic natural-killer cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, CD4+CD56+ hematodermic neoplasm, Langer lines
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved, IRB Protocol Number 12-328. |
© 2024
Publicado por Elsevier Masson SAS.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?